Legend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings

Reuters

05-23

Legend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings

Legend Biotech, a subsidiary of GenScript Biotech Corporation, is set to present new data on its CARVYKTI® therapy for patients with multiple myeloma at two major upcoming medical conferences. The data, part of the CARTITUDE Clinical Development Program, will be showcased at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association's (EHA) Congress. Legend Biotech, whose shares are listed on the Nasdaq Global Select Market, made this announcement following a Form 6-K filing with the United States Securities and Exchange Commission. For more detailed information, interested parties are encouraged to visit Legend Biotech's official website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2537973249"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537973249\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2537973249?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-23 07:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537973249","market":"us","top_or_hot":-1,"title":"Legend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Legend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Legend Biotech, a subsidiary of GenScript Biotech Corporation, is set to present new data on its CARVYKTI® therapy for patients with multiple myeloma at two major upcoming medical conferences. The data, part of the CARTITUDE Clinical Development Program, will be showcased at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association's (EHA) Congress. Legend Biotech, whose shares are listed on the Nasdaq Global Select Market, made this announcement following a Form 6-K filing with the United States Securities and Exchange Commission. For more detailed information, interested parties are encouraged to visit Legend Biotech's official website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-23 07:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Legend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Legend Biotech, a subsidiary of GenScript Biotech Corporation, is set to present new data on its CARVYKTI® therapy for patients with multiple myeloma at two major upcoming medical conferences. The data, part of the CARTITUDE Clinical Development Program, will be showcased at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association's (EHA) Congress. Legend Biotech, whose shares are listed on the Nasdaq Global Select Market, made this announcement following a Form 6-K filing with the United States Securities and Exchange Commission. For more detailed information, interested parties are encouraged to visit Legend Biotech's official website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000306685.HKD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL8rHtM7:1","article_id":"2537973249","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537973249","pubTimestamp":1747956543,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Legend Biotech, a subsidiary of GenScript Biotech Corporation, is set to present new data on its CARVYKTI therapy for patients with multiple myeloma at two major upcoming medical conferences. The data, part of the CARTITUDE Clinical Development Program, will be showcased at the 2025 American Society of Clinical Oncology  Annual Meeting and the European Hematology Association's  Congress. Legend Biotech, whose shares are listed on the Nasdaq Global Select Market, made this announcement following a Form 6-K filing with the United States Securities and Exchange Commission. For more detailed information, interested parties are encouraged to visit Legend Biotech's official website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Bi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK4139":"生物科技","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK4588":"碎股","BK1583":"高瓴概念","LEGN":"传奇生物","01548":"金斯瑞生物科技","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC"},"translate_title":"传奇生物将在2025年ASCO和EHA会议上公布治疗多发性骨髓瘤的新CARVYKTI数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":0.9,"LEGN":0.9},"content_text":"Legend Biotech to Reveal New CARVYKTI Data for Multiple Myeloma at 2025 ASCO and EHA Meetings\n    \n\n        Legend Biotech, a subsidiary of GenScript Biotech Corporation, is set to present new data on its CARVYKTI® therapy for patients with multiple myeloma at two major upcoming medical conferences. The data, part of the CARTITUDE Clinical Development Program, will be showcased at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association's (EHA) Congress. Legend Biotech, whose shares are listed on the Nasdaq Global Select Market, made this announcement following a Form 6-K filing with the United States Securities and Exchange Commission. For more detailed information, interested parties are encouraged to visit Legend Biotech's official website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}